Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
Dong‐Sung Lee, Eun-Sol Lee, Md. Morshedul Alam, et al.
Metabolism (2015) Vol. 65, Iss. 2, pp. 89-101
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Macrophage functions in lean and obese adipose tissue
Dylan D. Thomas, Caroline M. Apovian
Metabolism (2017) Vol. 72, pp. 120-143
Open Access | Times Cited: 252
FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity
Xiao-Qing Xiong, Zhi Geng, Bing Zhou, et al.
Metabolism (2018) Vol. 83, pp. 31-41
Closed Access | Times Cited: 135
Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
Christian Baumeier, Luisa Schlüter, Sophie Saussenthaler, et al.
Molecular Metabolism (2017) Vol. 6, Iss. 10, pp. 1254-1263
Open Access | Times Cited: 131
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
Elodie M. Varin, Erin E. Mulvihill, Jacqueline L. Beaudry, et al.
Cell Metabolism (2018) Vol. 29, Iss. 2, pp. 320-334.e5
Open Access | Times Cited: 119
The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice
Marta Olivares, Audrey M. Neyrinck, Sarah A. Pötgens, et al.
Diabetologia (2018) Vol. 61, Iss. 8, pp. 1838-1848
Open Access | Times Cited: 85
Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders
Yinhua Ni, Liyang Ni, Fen Zhuge, et al.
Obesity (2020) Vol. 28, Iss. 2, pp. 225-234
Closed Access | Times Cited: 80
Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
Anand-Krishna Singh, Dhananjay Yadav, Neha Sharma, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 586-586
Open Access | Times Cited: 61
Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF‐κB Signaling Pathway
Iman O. Sherif, Nora Hamad Al‐Shaalan
Oxidative Medicine and Cellular Longevity (2018) Vol. 2018, Iss. 1
Open Access | Times Cited: 73
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
Yochai Birnbaum, Dat Q. Tran, Mandeep Bajaj, et al.
Basic Research in Cardiology (2019) Vol. 114, Iss. 5
Closed Access | Times Cited: 62
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Laurie L. Baggio, Elodie M. Varin, Jacqueline A. Koehler, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 54
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Tianli Zhang, Tong Xiang, Shijie Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 49
Pectic polysaccharides from Aconitum carmichaelii leaves protects against DSS-induced ulcerative colitis in mice through modulations of metabolism and microbiota composition
Yuping Fu, Cen-Yu Li, Xi Peng, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113767-113767
Open Access | Times Cited: 30
Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials
John R. Ussher, Amanda A. Greenwell, My-Anh Nguyen, et al.
Diabetes (2022) Vol. 71, Iss. 2, pp. 173-183
Open Access | Times Cited: 28
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, et al.
Future Virology (2023) Vol. 18, Iss. 5, pp. 321-333
Open Access | Times Cited: 20
Parkinson';s Disease, Diabetes and Cognitive Impairment
Mohammad R. Ashraghi, Gennaro Pagano, Sotirios Polychronis, et al.
Recent Patents on Endocrine Metabolic & Immune Drug Discovery (2016) Vol. 10, Iss. 1, pp. 11-21
Open Access | Times Cited: 60
Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways
Ayman E. El-Sahar, Nesma A. Shiha, Nesrine S. El Sayed, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 2, pp. 158-169
Open Access | Times Cited: 39
Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
Roger Yazbeck, Simone Jaenisch, Catherine A. Abbott
Biochemical Pharmacology (2021) Vol. 188, pp. 114517-114517
Open Access | Times Cited: 36
DPP4 as a Potential Candidate in Cardiovascular Disease
Siyu Chen, Kong Xiangquan, Ke-Fan Zhang, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 5457-5469
Open Access | Times Cited: 23
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Dóra Balogh, László Wagner, Andrea Fekete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7789-7789
Open Access | Times Cited: 15
Vildagliptin inhibits high fat and fetuin-A mediated DPP-4 expression, intracellular lipid accumulation and improves insulin secretory defects in pancreatic beta cells
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 3, pp. 167047-167047
Closed Access | Times Cited: 5
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism
Erin E. Mulvihill
Peptides (2018) Vol. 100, pp. 158-164
Closed Access | Times Cited: 46
CD26 and Asthma: a Comprehensive Review
Juan José Nieto‐Fontarigo, Francisco Javier González‐Barcala, Esther San José, et al.
Clinical Reviews in Allergy & Immunology (2016) Vol. 56, Iss. 2, pp. 139-160
Open Access | Times Cited: 42
The protective role of DPP4 inhibitors in atherosclerosis
Hengdao Liu, Lingli Guo, Junhui Xing, et al.
European Journal of Pharmacology (2020) Vol. 875, pp. 173037-173037
Closed Access | Times Cited: 38
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Michał Wiciński, Karol Górski, Eryk Wódkiewicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2275-2275
Open Access | Times Cited: 33
DPP-4 exacerbates LPS-induced endothelial cells inflammation via integrin-α5β1/FAK/AKT signaling
Chang Liu, Jian Xu, Jiahao Fan, et al.
Experimental Cell Research (2024) Vol. 435, Iss. 1, pp. 113909-113909
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top